Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.4M
-
Number of holders
-
93
-
Total 13F shares, excl. options
-
44.2M
-
Shares change
-
+2.25M
-
Total reported value, excl. options
-
$517M
-
Value change
-
+$24.2M
-
Put/Call ratio
-
0.09
-
Number of buys
-
60
-
Number of sells
-
-25
-
Price
-
$11.70
Significant Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q2 2024
107 filings reported holding MLYS - Mineralys Therapeutics, Inc. - Common Stock as of Q2 2024.
Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 93 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.2M shares
of 77.4M outstanding shares and own 57.05% of the company stock.
Largest 10 shareholders include Catalys Pacific, LLC (9.19M shares), Samsara BioCapital, LLC (5.07M shares), RA CAPITAL MANAGEMENT, L.P. (4.85M shares), TCG Crossover Management, LLC (3.19M shares), BlackRock Inc. (2.05M shares), ORBIMED ADVISORS LLC (2.02M shares), SR One Capital Management, LP (2.02M shares), ADAMS STREET PARTNERS LLC (1.69M shares), FRANKLIN RESOURCES INC (1.48M shares), and Laurion Capital Management LP (1.46M shares).
This table shows the top 93 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.